Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

almotriptan

×

Overview

What is almotriptan?

Almotriptan tablets, USP contain almotriptan malate USP, a selective 5-hydroxytryptamine (5-HT) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine(±)-hydroxybutanedioate (1:1), and its structural formula is:

Its empirical formula is CHNOS-CHO, representing a molecular weight of 469.55. Almotriptan is a white to off-white crystalline powder that is soluble in water. Almotriptan tablets, USP for oral administration contains almotriptan malate equivalent to 6.25 or 12.5 mg of almotriptan. Each compressed tablet contains the following inactive ingredients: mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, polyethylene glycols, titanium dioxide and hypromelloses.



What does almotriptan look like?



What are the available doses of almotriptan?

Sorry No records found.

What should I talk to my health care provider before I take almotriptan?

Sorry No records found

How should I use almotriptan?

The recommended dose of almotriptan tablets, USP  in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. As individuals may vary in their response to different doses of almotriptan tablets, the choice of dose should be made on an individual basis.

If the headache is relieved after the initial almotriptan tablets dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four migraines in a 30-day period has not been established.


What interacts with almotriptan?

Sorry No Records found


What are the warnings of almotriptan?

Sorry No Records found


What are the precautions of almotriptan?

Sorry No Records found


What are the side effects of almotriptan?

Sorry No records found


What should I look out for while using almotriptan?


What might happen if I take too much almotriptan?


How should I store and handle almotriptan?

Shake well before using. Store at controlled room temperature 20° to 25°C (68° to 77°F). Dispense in a well-closed container as defined in the USP.Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Almotriptan tablets, USP are available as follows:6.25 mg:Carton of 6 tablets. Single blister of 6 tablets in each carton. NDC 27241-041-11 Blister of 6 tablets NDC 27241-041-6812.5 mg:Carton of 12 tablets. Two blisters of 6 tablets in each carton. NDC 27241-042-21Blister of 6 tablets NDC 27241-042-68Store at 25°C (77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
Cardiac Events and Fatalities with 5-HT

Agonists

Almotriptan tablets can cause coronary vasospasm; at least one of these events occurred in a patient with no cardiac history and with documented absence of coronary artery disease. Because of the close proximity of the events to use of almotriptan tablets, a causal relationship cannot be excluded. Patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of coronary artery disease (CAD) or a predisposition to Prinzmetal’s variant angina before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur.

Premarketing Experience with

Almotriptan

Tablets in Adults

Postmarketing Experience with

Almotriptan

Tablets in Adults

[see Adverse Reactions ()]

Patients with Documented Coronary Artery Disease

[see Contraindications ()].

 

Patients with Risk Factors for CAD

[see Contraindications ()].

For patients with risk factors predictive of CAD, who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of almotriptan tablets take place in the setting of a physician’s office or similar medically staffed and equipped facility unless the patient has previously received almotriptan tablets. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an ECG during the interval immediately following almotriptan tablets, in these patients with risk factors. It is recommended that patients who are intermittent long-term users of almotriptan tablets and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use almotriptan tablets.

The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to almotriptan tablets. The ability of cardiac diagnostic procedures to detect all cardiovascular diseases or predisposition to coronary artery vasospasm is modest at best. Cardiovascular events associated with triptan treatment have occurred in patients with no cardiac history and with documented absence of coronary artery disease.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).